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Episomal vector with the capacity to deliver a large gene 
containing all the critical regulatory elements is ideal for 
gene therapy. Human artificial chromosomes (HACs) 
have the capacity to deliver an extremely large genetic 
region to host cells without integration into the host 
genome, thus preventing possible insertional mutagen-
esis and genomic instability. Duchenne muscular dystro-
phy (DMD) is caused by mutation in the extremely large 
dystrophin gene (2.4 Mb). We herein report the devel-
opment of a HAC vector containing the entire human 
dystrophin gene (DYS-HAC) that is stably maintained 
in mice and human immortalized mesenchymal stem 
cells (hiMSCs). The DYS-HAC was transferred to mouse 
embryonic stem (ES) cells, and isoforms of the DYS-
HAC-derived human dystrophin in the chimeric mice 
generated from the ES cells were correctly expressed in 
tissue-specific manner. Thus, this HAC vector contain-
ing the entire dystrophin gene with its native regulatory 
elements is expected to be extremely useful for future 
gene and cell therapies of DMD.
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IntroductIon
Duchenne muscular dystrophy (DMD) is a recessive, fatal, 
X-linked disorder mainly caused by the absence of the dystrophin 
protein in skeletal muscle as well as in other tissues such as brain, 
retina, and smooth muscle, in which isoforms of dystrophin are 
normally expressed.1–5 Major current therapeutic approaches of 
DMD consist of (i) introducing (e.g., via viral or nonviral vectors) 
or repairing (e.g., via exon skipping) the genetic message, (ii) trans-
planting dystrophin-positive cells (e.g., via myoblast transplanta-
tion), or (iii) regulating synthesis of an endogenous gene product 
(e.g., via upregulation of utrophin gene expression).6,7 Several 
groups have reported various approaches to introduce genes for 
gene therapy.8,9 However, these vector systems have several clinical 
drawbacks including host genome integration, the limited ability 
to insert large genes, and an inappropriate expression. Random 
integration of the gene into the host genome may cause genomic 
instability and a misregulation of proximal gene loci adjacent to 
integration sites.10,11 Importantly, another possible problem is 
that an overexpression of a transgene can produce muscular dys-
trophy.12 Therefore, an exact dosage of the transgene is needed 
to achieve a therapeutic result in muscle gene therapy. Another 
approach of gene therapy is exon skipping. Exon skipping,  aiming 
to reading frame restoration, is a highly promising approach to 
convert the DMD phenotype into the milder Becker phenotype. 
However, exon skipping is a sequence-specific therapy which is not 
applicable to patients who have mutations in promoter regions or 
essential functional domains, and in the case of antisense oligo-
nucleotides, the readministration will also be necessary as these 
compounds have a limited half-life.7 For all these reasons, it would 
be desirable to target the dystrophin gene of DMD patients directly 
and permanently, independently from the nature of the mutation.
For more effective treatment of DMD, the development of a 
dystrophin expression vector that produces all isoforms of dys-
trophin may be required. Dystrophin gene encodes a number of 
tissue-specific isoforms of dystrophin including Dp427, Dp260, 
Dp140, Dp116, and Dp71 generated by transcription from at least 
seven promoters and also by alternative splicing.13 Until now, no 
episomal vector containing the entire dystrophin genomic region 
has been reported, because of its extremely large size (2.4 Mb).13,14
Human artificial chromosome (HAC) is a highly promising 
gene delivery tool that possesses several advantages over con-
ventional gene delivery systems. Like native chromosomes, HAC 
vectors have the capacity to replicate and segregate autonomously 
without integration into the host genome.15–24 In addition, HACs 
have the capacity to carry large genomic loci with their regulatory 
elements.25 The ideal gene delivery vector for safe gene therapy 
should be structurally defined and should not contain extra genes. 
We therefore recently produced a HAC vector by deleting all of the 
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endogenous genes on human chromosome 21. This HAC contains 
an enhanced green fluorescent protein (EGFP) gene for visualiz-
ing, the herpes simplex virus thymidine kinase (HSV-tk) gene for 
the elimination of itself and a loxP site for cloning of a transgene.
In this study, we developed a HAC vector containing the 
entire human dystrophin gene including its all transcriptional 
regulatory elements (DYS-HAC). We confirmed that the multiple 
tissue- specific isoforms of human dystrophin were produced in 
mice containing the DYS-HAC, and the DYS-HAC was stably 
maintained in mice and cultured human cells.
results
targeted integration of a loxP site into the 
proximal loci to the dystrophin gene on 
a human X chromosome fragment
We performed the following experiments to develop a HAC 
 containing the entire dystrophin gene using the chromosome 
engineering. The overall strategy for vector construction is shown 
schematically in Figure 1. We have previously established mono-
chromosomal hybrids containing individual human chromo-
somes.26 In this study, a human X chromosome fragment was 
transferred from A9 cells into DT40 cells by microcell-medicated 
chromosome transfer (MMCT), because DT40 cells exhibit a high 
frequency of homologous recombination between an exogenous 
DNA template and its chromosomal counterparts.27 This human 
X chromosome fragment containing the dystrophin gene was 
originally derived from the human primary fibroblast cells by 
MMCT. Initially, to integrate a loxP site containing the drug-re-
sistant marker blasticidin S deaminase (bsd) and the 3′ hypoxan-
thine phosphoribosyl transferase (HPRT) into the proximal loci to 
the human dystrophin gene, the loxP targeting vector, pDYS-H3 
was introduced into the DT40 hybrid cells retaining a single copy 
of human X chromosome fragment tagged with the neomycin-
 resistant gene (Figure 2a). PCR analyses using the primers (BsdR/
DloxP3R, DloxP4L/4R and DloxP5L/DloxP3R) showed that 2 of 
11 blasticidin S Hydrochloride (BS)-resistant transfectants were 
correctly targeted (Tables 1 and 2). By fluorescence in situ hybrid-
ization (FISH), the digoxigenin-labeled human Cot1 DNA probe 
localized to an independently segregating X chromosome frag-
ment and the biotin-labeled bsd probe localized at the proximal 
region on the human X chromosome fragment. Neither insertion 
nor translocation were observed in both clones (Figure 2c and 
Table 2). These results indicate that the loxP site was successfully 
targeted in the correct location. These two clones were used for 
a targeted truncation of the distal region of the dystrophin gene on 
this human X chromosome fragment.
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Figure 1 schematic diagram of the construction of various cells containing the dYs-HAc vector. The human dystrophin is located on the short 
arm of the human X chromosome. Chromosome manipulation was carried out in homologous recombination-proficient DT40 cells. To clone human 
dystrophin gene into the human artificial chromosome (HAC) vector using the Cre-loxP mediated chromosomal translocation, a loxP was targeted to 
the proximal locus of the dystrophin gene on the human X chromosome. Extra genes on the distal of the dystrophin gene were deleted by telomere-
associated chromosome truncation in the DT40 cells. The modified human X chromosome fragment was transferred into Chinese hamster ovary 
(CHO) hybrids containing the HAC including the loxP vector by microcell-medicated chromosome transfer (MMCT). The dystrophin gene (2.4 Mb) 
was cloned into the HAC vector in CHO cells using Cre-loxP mediated chromosomal translocation. From the CHO hybrids, the DYS-HAC vector was 
further transferred to human immortalized mesenchymal stem cells (hiMSCs) and mouse embryonic stem (ES) cells. The stability of the DYS-HAC 
was investigated in hiMSC cells. To study the expression of the human dystrophin gene on the DYS-HAC in vivo, the chimeric mice were produced 
from the ES cells containing the DYS-HAC.
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targeted truncation of the distal region of the 
dystrophin gene on the human X chromosome
The terminal regions from the dystrophin gene on the X chro-
mosome fragment were deleted in DT40 cells using the telomere-
 associated chromosome truncation, which is the combined use 
of gene targeting and telomere-mediated chromosome breakage 
to generate a defined truncation of a human chromosome.16,28  
A  targeting construct containing the region homologous to the distal 
region of the dystrophin gene, the selectable marker gene, puromy-
cin and 1 kb of telomeric sequence repeats, pDYS-tel2, was trans-
fected to the DT40 cells containing the loxP site-targeted human 
X chromosome fragment (Figure 2b). Two hundred and sixty-five 
 puromycin-resistant transfectants were isolated and first screened 
by PCR analyses with primers for the detection of the distal region 
(PRKX F/R and FTHL17 F/R). Eighteen of 265 clones showed the 
expected patterns of marker retention. Next, four of eight clones 
randomly selected among them showed the expected pattern 
of marker retention by PCR analyses with all other  primers 
(Figure 2b, Tables 1 and 2). FISH analysis with the biotin- labeled 
PGK-puro probe and the digoxigenin-labeled human Cot1 DNA 
probe revealed that the human X  chromosome fragment was 
 truncated at the distal region of the dystrophin gene and the 
fragment  segregated  independently without either host genome 
 insertion or translocation in all four clones (Figure 2d). These 
results indicate that the genes on the distal from the dystrophin 
gene were deleted at the defined locus by the  telomere-associated 
chromosome truncation strategy.
transfer of the modified X chromosome fragment 
from the dt40 cells to the chinese hamster  
ovary (cHo) hybrids containing the HAc vector
The truncated X chromosome fragment containing the human 
dystrophin gene and the 3′ HPRT-loxP was transferred from the 
DT40 cells into the CHO cells containing the HAC vector includ-
ing the 5′ HPRT-loxP using MMCT. Sixty G418-resistant CHO 
clones were obtained from three independent DT40 clones con-
taining the modified X chromosome fragment as donor cells. 
PCR analyses with primer sets for the detection of the HAC and 
the modified X chromosome showed that 11 of 60 CHO hybrids 
retained both the HAC vector and the modified X chromosome 
(Table 1). FISH analyses showed the HAC vector and the modi-
fied X chromosome to be independently present in 9 of 10 clones 
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Figure 2 construction of the dYs-HAc vector. (a) Strategy for the targeted integration of the loxP site into the proximal loci to the dystrophin gene 
on the human X chromosome fragment by the loxP targeting vector pDYS-H3. (b) Strategy for the targeted truncation of the distal region of the dys-
trophin gene on the X chromosome by the targeting vector pDYS-tel2. (c–f) Fluorescence in situ hybridization analyses of the modified chromosomes 
in the DT40 or the Chinese hamster ovary (CHO) hybrid cells. Chromosomal DNA was counterstained with DAPI. The digoxigenin-labeled human 
Cot1 DNA (red) detected the human chromosome fragment in the each hybrid. (c) The targeted loxP site on the human X chromosome fragment in 
DT40 backgrounds, hybridized to the biotin-labeled CMV-bsd probe (green), is indicated with an arrowhead. (d) The truncated site on the human X 
chromosome in DT40 backgrounds, hybridized to the biotin-labeled PGK-puro (green), is indicated with an arrowhead. (e) The dystrophin gene on 
the modified human X fragment in CHO backgrounds, hybridized to the bacterial artificial chromosome (BAC) (RP11-954B16) containing the part 
of the dystrophin genome (green), is indicated with an arrowhead. An arrow indicates the human artificial chromosome (HAC) and the insets show 
enlarged images of the HAC vector and the modified human X fragment. (f) The region of dystrophin gene on the DYS-HAC in CHO backgrounds, 
hybridized to the biotin-labeled BAC (RP11-954B16) containing a part of the human dystrophin genome (green), is indicated with an arrowhead. 
The insets show enlarged images of the DYS-HAC and the X/HAC fragment. (g) The map of the DYS-HAC vector. The DYS-HAC vector contains the 
enhanced green fluorescent protein (EGFP) gene, the herpes simplex virus thymidine kinase (HSV-tk) gene, and several selection markers (bsd, puro-
mycin, and HPRT gene). Both telomeres of the DYS-HAC are artificial. The centromere of the DYS-HAC is derived from human chromosome 21.
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randomly selected among them (Figure 2e and Table 2). The 
efficiency of MMCT from DT40 cells to CHO cells was 5 × 10−6, 
which is comparable to our previous results.29
cloning of the human dystrophin gene into the HAc 
vector by a cre-mediated site-specific translocation
In order to clone only the human dystrophin gene into the 
HAC vector containing a 5′ HPRT-loxP using the Cre-loxP 
system, CHO hybrids containing the HAC and the modi-
fied human X chromosome including a 3′ HPRT-loxP 
were transfected with the Cre-recombinase expression vec-
tor. Intra- and intermolecular recombination between two 
loxP sites is efficiently promoted using Cre-recombinase.30  
A loxP-mediated site-specific translocation reconstitutes a 
 functional HPRT gene, which confers HAT-resistance. Fifty-
three HAT-resistant CHO clones were obtained using two inde-
pendent CHO hybrids. The translocation confirmed in 16 of 53 
CHO clones by PCR analysis (Tables 1 and 2). In addition, FISH 
analysis confirmed that the bacterial artificial chromosome (BAC) 
probe signal containing the part of human dystrophin gene was 
table 1 summary of the expected pattern in hybrid cell lines by Pcr analyses
no.a 1 2 3 4 5 6 7 8
cell line
dt40 cells 
containing 
the human  
X chromo-
some
dt40 cells 
containing 
the loxP 
site-targeted 
human X  
chromosome
dt40 cells 
containing 
the loxP 
site-targeted 
and truncated 
human X 
chromosome
cHo cells  
containing 
the HAc
cHo cells 
containing 
the modified 
human X  
chromosome 
and the  
HAc
cHo cells 
containing  
the dYs-HAc
es cells  
containing 
the  
dYs-HAc
hiMscs  
containing 
the  
dYs-HAc
Product 
size
Purpose Primer
X chromo 
some 
truncation
PRKX F/R + + − NT NT NT NT NT 131 bp
ARHGAP6 F/R + + − NT NT NT NT NT 150 bp
TAB3 F/R + + − NT NT NT NT NT 137 bp
FTHL17 F/R + + − NT NT NT NT NT 298 bp
Sk23/DYSt5R − − + − + + + + 8.8 kb
Sk23/DYSt6R − − + − + + + + 9.1 kb
PuroI/DYSt5R − − + − + + + + 9.8 kb
PuroI/DYSt6R − − + − + + + + 10.1 kb
Human 
dystrophin 
retention
DYS1L/DYS1R + + + − + + NA NA 168 bp
DYS1L/DYS2R + + + NA NA NA NA NA 331 bp
DYS2L/DYS2R + + + NA NA NA NA NA 177 bp
DYS3L/DYS3R + + + NA NA NA + NA 163 bp
DYS4L/DYS4R + + + − + + + NA 128 bp
DYS5L/DYS5R + + + − + + + NA 132 bp
DYS6L/DYS6R + + + − + + + NA 170 bp
DYS6L/DYS7R + + + NA NA NA NA NA 318 bp
DYS7L/DYS7R + + + − + + + NA 151 bp
DYS7L/DYS8R + + + − + + + NA 706 bp
DYS8L/DYS8R + + + − + + + NA 155 bp
The loxP 
targeting
BsdR/DloxP3R − + + − + − − − 7.5 kb
DloxP4L/DloxP4R + − − NT NT NT NT NT 3.1 kb
Dloxp5L/Dloxp3R + − − NT NT NT NT NT 6.6 kb
The HAC  
vector  
retention
PuroI/Pcen1L − − − + + + + + 6.1 kb
EGFPL/#21 
CenG6R
− − − + + + + + 6.0 kb
PGKr2/#21 
Cen<1>2L
− − − + + + + + 4.5 kb
Sk23/q2L − − − + + − − − 7.4 kb
HPRT 
reconstitution
TransL1/R1 NT NT NT − − + + NA 409 bp
aDescribed in Figure 1.
CHO, Chinese hamster ovary; ES, embryonic stem; HAC, human artificial chromosome; hiMSC, human immortalized mesenchymal stem cell; HPRT, hypoxanthine 
phosphoribosyl transferase; NA, not applicable due to detection of endogenous genome; NT, not tested.
Molecular Therapy  vol. 17 no. 2 feb. 2009 313
© The American Society of Gene Therapy
HAC Containing the Dystrophin Gene
hybridized with the DYS-HAC and the DYS-HAC was  present as 
an independent minichromosme without integration into the host 
genome in all 11 clones randomly selected among them (Figure 2f 
and Table 2). These results indicate that the DYS-HAC was suc-
cessfully developed by cloning the human dystrophin gene into 
the HAC vector.
Generation of mouse embryonic stem (es) cells 
containing the dYs-HAc vector and production of 
chimeric mice
To investigate whether the DYS-HAC vector shows physiologi-
cal expression of the human dystrophin gene, we produced 
the chimeric mice containing the DYS-HAC vector. First, the 
DYS-HAC was transferred from the CHO hybrids into mouse 
ES cells using MMCT technique. Thirty BS-resistant ES clones 
were obtained using three independent CHO cells containing the 
DYS-HAC vector as donor cells. In 12 of 30 drug-resistant ES 
hybrids, the DYS-HAC loci were detected and the expected pat-
terns were showed by PCR (Figure 3a and Table 1). A FISH anal-
ysis showed that independently segregating the DYS-HAC was 
observed without insertion into host genome and the karyotype 
of mouse backgrounds was normal in 7 of 12 ES hybrids which 
showed the expected patterns by PCR (Figure 3b and Table 2). 
The efficiency of MMCT from CHO hybrids to ES cells was 1.8 × 
10−7. The protein produced from the cytomegalovirus enhancer/
chicken β-actin promoter driven EGFP gene on the DYS-HAC 
was detected in mouse ES cells containing the DYS-HAC by fluo-
rescence microscopy (Figure 3c). Three independent ES hybrids 
containing the DYS-HAC clones were used to produce viable chi-
meric mice. Chimeric mice with up to 60% coat color chimerism 
were produced. The germline transmission of the DYS-HAC to 
the progency mice was not observed using the chimeric mice 
(data not shown).
expression of the EGFP gene and the human 
dystrophin gene in various tissues of the chimeras
We examined the stability of the DYS-HAC and the human 
dystrophin gene expression from the DYS-HAC in four chi-
meric mice containing the DYS-HAC. The EGFP gene driven 
table 2 the results in the screening of the various clones isolated for this study
clone no.a
experimental  
method and scale
drug  
resistant 1st Pcr 2nd Pcr FIsH chromosome engineering
DT40 cells containing the 
loxP site-targeted human X 
chromosome
2 3 EP 11 2/11 2/2 2/2 Targeted integration of a loxP site 
on the human X chromosome 
fragment proximal to the 
dystrophin gene
DT40 cells containing the loxP 
site-targeted and truncated  
human X chromosome
3 3 EP 265 18/265 4/8 4/4 Targeted truncation of the 
distal region on the human X 
chromosome fragment
CHO cells containing the 
modified human X chromosome 
and the HAC
5 12 F 60 NT 11/60 9/10 Transfer of the modified human X 
chromosome fragment from DT40 
cell to CHO cells containing a 
HAC vector
CHO cells containing  
the DYS-HAC
6 4 LP 53 NT 16/53 11/11 Cloning of human dystrophin gene 
into the HAC vector by a Cre-
mediated site-specific translocation
ES cells containing the DYS-HAC 7 17 F 30 NT 12/30 7/12 Transfer of the DYS-HAC from 
CHO cells to ES cells
hiMSCs containing the DYS-HAC 8 2 F 14 NT 3/4 2/3 Transfer of the DYS-HAC from 
CHO cells to hiMSCs
aDescribed in Figure 1.
CHO, Chinese hamster ovary; EP, electroporation; ES, embryonic stem; FISH, fluorescence in situ hybridization; HAC, human artificial chromosome; hiMSC, human 
immortalized mesenchymal stem cell; LP, lipofection; F, fusion by microcell-medicated chromosome transfer; NT, not tested.
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Figure 3 transfer of the dYs-HAc vector into the mouse embryonic 
stem (es) cells. (a) The detection of the human dystrophin gene of the DYS- 
HAC-transferred ES hybrids by PCR analyses using the human dystrophin-
specific primers. The ES cells and the Chinese hamster ovary (CHO) cells 
were used as negative controls. The CHO cells containing the DYS-HAC 
and the human fibroblasts were used as positive controls. (b) A fluores-
cence in situ hybridization analysis in the ES cells is shown. The DYS-HAC 
vector, hybridized to the digoxigenin-labeled human Cot1 DNA probe 
(red), is indicated with an arrowhead. The dystrophin gene hybridized 
to the biotin-labeled bacterial artificial chromosome (RP11-954B16) 
containing the part of the human dystrophin genome (green). The inset 
shows enlarged images of the DYS-HAC vector. (c) The expression of the 
enhanced green fluorescent protein (EGFP) gene on the DYS-HAC was 
tracked in living cells by fluorescence microscopy.
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by chicken β-actin promoter on the DYS-HAC was expressed 
in all examined tissues of the chimeric mice including intes-
tine, brain, kidney, spleen, liver, heart, lung, thymus, skeletal 
muscle, and uterus (Figure 4a), suggesting that the DYS-HAC 
was stably maintained in vivo. To investigate whether the 
human dystrophin gene on the DYS-HAC vector was appro-
priately expressed, total RNAs from various tissues of the chi-
meras were analyzed by reverse transcription–PCR using three 
pairs of specific primers to detect the human dystrophin tissue-
 specific transcripts. Using the DYS140e1L/DYSe45R primer 
sets, transcripts of human dystrophin from the DYS-HAC chi-
mera were found mainly in brain as well as those from human 
used as control. Using the primer pairs of DYS427me1L/1R and 
DYS427le1L/DYSe3R, transcripts of human dystrophin from the 
DYS-HAC chimera were detected mainly in the heart,  skeletal 
muscle, and uterus, as well as in those from normal human, 
whereas the genomic dystrophin were detected in all examined 
tissues using the DYS427me1L/1R primer sets (Figure 4b,c). 
An immunostaining analysis using human dystrophin-specific 
antibody showed the human dystrophin protein to be localized 
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Figure 4 expression of enhanced green fluorescent protein (EGFP) and human dystrophin in various tissues of the chimeric mice containing 
the dYs-HAc. (a) The EGFP gene on the DYS-HAC was expressed in all examined tissues of the chimeric mice (intestine, brain, kidney, spleen, liver, 
heart, lung, thymus, skeletal muscle, and uterus). (b) The positions of primers for detecting dystrophin isoforms are shown. The black boxes show 
exons. The sequence of the DYS427le1L primer is located at the Dp427l isoforms but not at the Dp427m isoforms. (c) The expression of the human 
dystrophin gene derived from the DYS-HAC in each tissue of the chimeric mice containing the DYS-HAC vector was detected by reverse transcription–
PCR using three different sets of the human dystrophin-specific primers. EGFP and GAPDH were used as internal controls. cDNA from C57BL/6 mouse 
tissues and human cDNA were used as a negative and a positive control, respectively. DNA from the tissues of the chimera containing the DYS-HAC 
was used as a control. (d) An immunofluorescence analysis of muscle biopsies from the chimeras containing the DYS-HAC vector, stained with the 
anti-human dystrophin-specific antibody (red). C57BL/6 mouse muscle tissue was used as a negative control. The expression of the EGFP gene on the 
DYS-HAC was tracked by fluorescence microscopy. Representative photographs are shown.
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at the sarcolemmal membrane in muscle (Figure 4d).14,31,32 These 
results suggested that the isoforms of human dystrophin gene on 
the DYS-HAC vector were tissue-specifically expressed in the 
mouse genetic background, and the protein of the human dystro-
phin was localized at the correct locus.
stability of the dYs-HAc vector in human cells
To investigate the stability of the DYS-HAC in human cell, the 
DYS-HAC was transferred into the human immortalized mes-
enchymal stem cells (hiMSCs).33 Fourteen hiMSC hybrids were 
selected with BS, and four clones randomly selected among them 
were screened by PCR and FISH analyses. In two of four clones, 
successful transfer was observed (Tables 1 and 2, Figure 5a). 
The stability of the DYS-HAC vector was tested in the human 
cell line using the two hiMSCs containing the DYS-HAC. The 
cell lines were split and maintained independently either in 
medium with BS or without any selection. The retention of the 
DYS-HAC vector in the two sublines (both with and without 
selection) was assessed in 100 interphases and 20 metaphases 
at 25, 50, 75, and 100 population-doubling levels by the FISH 
analysis. The retention rate of the DYS-HAC vectors in the hiM-
SCs background remained in almost 100% of interphases by 
100 population-doubling levels even without the BS-selection 
(Figure 5b). No rearrangement was observed in the metaphases 
at 100 population-doubling levels (data not shown). Silencing of 
EGFP gene expression on the DYS-HAC was not observed in the 
hiMSCs containing the DYS-HAC at 100 population-doubling 
levels (Figure 5c). These results indicate that the DYS-HAC 
vector in the human cells is stable without integration into the 
host genomes even after long-term culture in vitro.
dIscussIon
We herein report the development of a HAC containing the 
entire dystrophin gene as a potential strategy for the treatment 
of DMD. The entire human dystrophin genome is unusually large 
and beyond the capability of viral vector systems.6 One  important 
advantage of the HAC system report here is no apparent size 
limitation of inserted transgenes.34 We thus inserted the entire 
 dystrophin gene within this HAC vector.
Dystrophin has a complicated regulation of expression system 
including proper levels of expression and important functional 
isoforms that require selective promoter usage and highly regu-
lated RNA processing events. Previously reported vector systems 
drove expression of dystrophin by the heterologous promoters that 
produced only one dystrophin isoform, mainly the 427 kDa dys-
trophin isoform.8 Since the DYS-HAC vector used here contains 
the entire dystrophin gene with all known regulatory elements, we 
found evidence that at least three dystrophin isoforms were pro-
duced. Recently, Hoen et al. reported the development of a yeast 
artificial chromosome vector containing the entire human dystro-
phin gene that was successfully introduced into mice.35 However, 
yeast artificial chromosome vector systems require the random 
integration of the transgene into the host genome creating the pos-
sibility of alteration of gene regulation and genomic  instability.36 
In contrast, this study demonstrates that the DYS-HAC can be 
maintained in host cells as an independent minichromosome 
without integration into the host genome. The DYS-HAC contains 
the entire dystrophin gene with all its known native regulatory ele-
ments and its copy number is one similarly to native dystrophin 
subjected to X-inactivation. Therefore, unlike other vector  systems 
in which dystrophin expression was driven by heterologous pro-
moters resulting in an aberrant protein steady state levels,12 the dys-
trophin produced from the DYS-HAC vector is expressed at levels 
similar to native dystrophin expression levels and isoform produc-
tion. More importantly, the DYS-HAC can be repeatedly used for 
transferring to different host cells, whereas the other  systems are 
expected to cause different results in each host cell.
Regarding future DMD treatment strategies, the DYS-HAC 
may perhaps be introduced into several types of patient stem or 
progenitor cells for ex vivo therapy, e.g., induced pluripotent stem 
cells, mesoangioblasts, and mesenchymal stem cells.37–41 The DYS-
HAC also contains a “suicide” gene encoding the HSV-tk gene as a 
backup system to specifically eliminate cells containing this  vector. 
The cells containing the DYS-HAC can be specifically killed by 
ganciclovir, for example, if they induce a cellular abnormality 
such as carcinogenesis after transplantation. In addition, the mice 
obtained by crossing dystrophin-deficient mice with mice con-
taining the DYS-HAC can also be used for functional and genetic 
studies. Therefore, the DYS-HAC vector will be useful not only for 
the treatment of DMD genetic disorders, but also for applications 
in animal transgenesis.
In conclusion, the DYS-HAC vector system reported herein 
is a unique nonintegrating vector maintaining the ability to 
 incorporate exceptionally large regions of DNA and is highly 
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Figure 5 retention of the dYs-HAc in the human immortalized mes-
enchymal stem cells (hiMscs). (a) A fluorescence in situ hybridization 
(FISH) analysis in the hiMSCs is shown. The dystrophin gene on the DYS-
HAC, hybridized to the biotin-labeled bacterial artificial chromosome 
(BAC) (RP11-954B16) containing the part of human dystrophin genome 
(green), is indicated with an arrowhead. The insets show the DYS-HAC 
and the endogenous human X chromosome. (b) Retention of the DYS-
HAC was determined by FISH using the biotin-labeled dystrophin BAC 
(RP11-954B16) after a long period of culture with and without selection. 
(c) The expression of the EGFP gene on the DYS-HAC was tracked in 
living cells by fluorescence microscopy. Representative photographs are 
shown. PDL, population-doubling level.
316 www.moleculartherapy.org  vol. 17 no. 2 feb. 2009 
© The American Society of Gene Therapy
HAC Containing the Dystrophin Gene
stably maintained as an episomal element in host cells. Although 
the transferring efficiency of chromosome via MMCT need to be 
improved for cells with a limited life span, the current technology 
is sufficient for isolation of the immortalized stem cells with HACs 
transferred by ex vivo. When the HAC vector meets more sophis-
ticated technologies of cellular differentiation to come in a near 
future, this nonintegrated episomal vector will facilitate various 
gene and cell therapies. Thus, the construction of the DYS-HAC 
is an initial step for the DMD-gene therapy. Future studies using 
DMD animal models with autologous genetically corrected stem 
cells containing the DYS-HAC vector will elucidate the efficacy of 
ex vivo gene therapy.
MAterIAls And MetHods
Cell culture. The DT40 hybrid cells were maintained in Roswell Park 
Memorial Institute medium 1640 (Invitrogen, Carlsbad, CA) contain-
ing 10% fetal bovine serum (Biowest, Nuaillé, France), 1% chicken serum 
(Invitrogen), 50 µmol/l 2-mercaptoethanol (Sigma, St Louis, MO) and 
the appropriate  antibiotics. The DT40 hybrids containing a single copy 
of human X chromosome  fragment (a long arm deletion of X chro-
mosome) were produced by MMCT from mouse A9 cells containing 
its fragment (established by Dr Hanaoka; unpublished) and main-
tained with 1.5 mg/ml G418 (Invitrogen). The HPRT-deficient CHO 
(JCRB0218) hybrids containing the HAC vector were constructed pre-
viously and maintained in Ham’s F-12 nutrient mixture (Invitrogen) 
plus 10% fetal bovine serum with 8 µg/ml BS (Funakoshi, Tokyo, Japan). 
The HAC contains no endogenous genes, with modifications from the 
original one,19 i.e., containing an EGFP gene and the HSV-tk gene. hiM-
SCs were maintained in Dulbecco’s modified Eagle’s medium (Sigma) 
supplemented with 10% fetal bovine serum.33 Mouse ES cell culture 
(TT2-F, isolated from TT2) was performed as described previously.26
Construction of targeting vectors. The targeting vector, pDYS-H3 for 
introducing 3′ HPRT-loxP/bsd/tk, was constructed as follows: two 2.6 kb 
and 6.1 kb fragments for homologous arms corresponding to human 
dystrophin locus in AL050305 were amplified by PCR using primers 
DloxP4L/4R (3.1 kb), 5′-TCCACACGCCCTTTGATAGGAATAGGAT-3′ 
and 5′- CATCTGAGGGTTTTGGTTCTCGGTTTTC-3′; DloxP5L/5R 
(6.6kb), 5′-TGGAGAGAGTGAAGAGGGAAGGAGGAAA-3′ and 5′-CA 
CCTGCAGAACTCTCCACCCAAAAGTA-3′, digested with either EcoRI 
or BglII and sub-cloned into the equivalent sites of pKO Scrambler V901 
backbone vector (Lexicon Genetics, Woodlands, TX), respectively, which 
contained the following three selection/insertion cassettes between the 
EcoRI and BglII sites: a 2 kb fragment from pMC1-tk (Stratagene, La 
Jolla, CA) containing the HSV-tk gene, a 2.3 kb XbaI/AscI fragment 
from pKO SelectHPRT V820 (Lexicon Genetics) containing the part of 
human HPRT gene with loxP site inserted at XbaI site of intron B and a 
1.3 kb XhoI fragment from pCMV/bsd (Invitrogen) encoding the bsd 
gene. For construction of the chromosome truncation vectors pDYS-tel2, 
a PCR product from the human dystrophin locus in AC006060 was ampli-
fied by PCR with the following primers DYSt5L/5R (8.8 kb), (5′-TAAGG 
ATCCCCCTCATTGTAGCGAAGAGCAGG-3′ and 5′- CTGAGCCCTCA 
CCAGAATCACCTTGATA-3′), digested with both EcoRI and BamHI 
(7.5 kb) and sub-cloned into the EcoRI/BamHI sites of pBS-TEL/Puro 
vector.16
MMCT. The modified X fragment containing the human dystrophin gene 
and the 3′ HPRT-loxP was transferred from the DT40 hybrids into the 
CHO hybrids containing the HAC vector by MMCT technology.34 Briefly, 
microcells were prepared by centrifuge of 1 × 109 DT40 cells attached on 
flasks (Nalge Nunc, Rochester, NY) coated with poly-L-lysine (Sigma) and 
were fused to 1 × 106 CHO cells by 47% polyethylene glycol 1000 (WAKO, 
Osaka, Japan). CHO hybrids were selected in 0.8 mg/ml G418 and picked 
for expansion. After construction of the HAC vector containing the entire 
human dystrophin gene (DYS-HAC) by the site-specific translocation in 
CHO hybrids, transfer of the DYS-HAC vector from CHO cells to hiM-
SCs or mouse ES cells was performed using standard procedures.26,42 
The hiMSC hybrids were selected in 4 µg/ml BS and the ES hybrids were 
selected in 4 µg/ml BS.
Genomic PCR analyses. Genomic DNA from cell lines and chimeric 
 tissue specimens was extracted using a genomic extraction kit (Gentra 
System, Minneapolis, MN). PCR analyses were carried out using stan-
dard techniques. The primer pairs for the detection of the chromo-
some truncation at the AC006060 locus were: Sk23/DYSt5R (8.8 kb), 
5′-GGCCGCTCTAGAACTAGTGGATC-3′ and 5′-CTGAGCCCTCACCA 
GAATCACCTTGATA-3′; Sk23/DYSt6R (9.1 kb), 5′-CACACCACTTTTT 
GAGTCCTTTGCTGCT-3′; PuroI/DYSt5R (9.8 kb), 5′-GAGCTGCAA 
GAACTCTTCCTCACG-3′; PuroI/DYSt6R (10.1 kb). The primer pairs for 
the confirmation of deleted loci of distal region on the modified human 
X  chromosome fragment by the telomere-associated chromosome trunca-
tion were: PRKX F/R (131 bp), 5′-CTTCACGGCATAAGGACATCTC-3′ 
and 5′-TTCAAAACCTTCCTACAGTGTGG-3′; ARHGAP6 F/R (150 bp), 
5′-CCACTGGGAATTTCATCACC-3′ and 5′-ATTTTTGACCAGCAGAT 
GGC-3′; TAB3 F/R (137 bp), 5′-TGGCACAAAGTTTTATCTGTGC-3′ and 
5′-CCATTCCAAAATCCATTTGG-3′; FTHL17 F/R (298 bp), 5′-TGGCCC 
TGGAGAACTTCTT-3′ and 5′-ATGGTCTTGACTTGCTCGTG-3′. The 
primer pairs for the detection of the region of human dystrophin gene 
were: DYS1L/1R (168 bp), 5′- TGCTCTGGCTCATGTGTTTGC-3′ and 
5′-AGCTCCCCTTTCGCATGATTC-3′; DYS1L/2R (331 bp), 5′- CCA 
TGCCAGCTGTTTTTCCTG-3′; DYS2L/2R (177 bp), 5′- CGAAAGGGG 
AGCTGTTGGAAT-3′; DYS3L/3R (163 bp), 5′-AACAACTGAAC 
AGCCGGTGGA-3′ and 5′-GGGGTGGTGGGTTGGATTTT-3′; DYS4L/ 
4R (128 bp), 5′-GCAAGAGCAACAAAGTGGCCTA-3′ and 5′-AGCTTCTT 
CCAGCGTCCCTCA-3′; DYS5L/5R (132 bp), 5′-ACCTTCAGAA 
CCGGAGGCAAC-3′ and 5′-AGGGACCCTCCTTCCATGACTC-3′; 
DYS6L/6R (170 bp), 5′-TGGAACGCATTTTGGGTTGTT-3′ and 5′-AAAA 
CAATGCGCTGCCTCAAA-3′; DYS6L/7R (318 bp), 5′-AAACTCAA 
GCCTGCCCCACTC-3′; DYS7L/7R (151 bp), 5′-TTTGCATCCTTTT 
GGCGTGAT-3′; DYS7L/8R (706 bp); DYS8L/8R (155 bp), 5′-GCTGCTAGC 
AATGCCACGATT-3′ and 5′-GGATGGGCTGGGAATCCATAG-3′. 
The primer pairs for the detection of the loxP site targeting were: BsdR/
DloxP3R (7.5 kb), 5′-GCTCAAGATGCCCCTGTTCT-3′ and 5′-CACCT
GCAGAACTCTCCACCCAAAAGTA-3′; DloxP4L/4R (3.1 kb), 5′-TCCA
CACGCCCTTTGATAGGAATAGGAT-3′ and 5′-CATCTGAGGGTTTT
GGTTCTCGGTTTTC-3′; DloxP5L/DloxP3R (6.6 kb), 5′-TGGAGAGAG
TGAAGAGGGAAGGAGGAAA-3′. The primer pairs for the detection of 
the markers on the HAC vector were: PuroI/ Pcen1L (6.1 kb), 5′-ACTG
CTGCCATGCAGACAGTTGTGCTTT-3′; EGFPL/#21CenG6R (6.0 kb), 
5′-CCTGAAGTTCATCTGCACCA-3′ and 5′-CCCGGCCAGATTCAGA
TTTTTATTAGGG-3′; PGKr2/#21Cen<1>2L (4.5 kb), 5′-ATCTGCACGA
GACTAGTGAGACGTGCTA-3′ and 5′-AAATGCATCACCATTCTCCCA
GTTACCC-3′; Sk23/ q2L (7.4 kb), 5′-TCATGCCACAATCAATCTCCCAA
GTAGC-3′. The primer pairs for the detection of the HPRT gene reconstruc-
tion were: TransL1/R1 (409 bp), 5′-TGGAGGCCATAAACAAGAAGAC-3′ 
and 5′-CCCCTTGACCCAGAAATTCCA-3′.
Reverse transcription–PCR analyses. Total RNA was prepared from chi-
meric tissue specimens using ISOGEN (Nippon Gene, Tokyo, Japan). 
Prepared RNA was treated with RNase-free DNase I (WAKO) and cleaned 
up using RNeasy columns according to the manufacturer’s instructions 
(Qiagen, Hilden, Germany). First-strand cDNA synthesis was carried out 
using an oligo-(dT)20 primer and the SuperScript III reverse transcriptase 
(Invitrogen). Human tissue cDNAs from the multiple tissue cDNA panel 
I and II (Clontech, Palo Alto, CA) were used as a control. PCR was 
 performed with the cDNA using AmpliTaq Gold (Perkin Elmer, Waltham, 
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MA). Amplifications were performed with an annealing temperature of 
58 °C for 30–35 cycles and then the amplified fragments were resolved by 
electrophoresis on a 2% agarose gel, followed by staining with ethidium 
bromide. The primer sequences were as follows: for dystrophin, DYS 
427me1L/DYS427me1R (211 bp), 5′-TTCCCCCTACAGGACTCAGA-3′ 
and 5′-TCTTCCCACCAAAGCATTTT-3′; DYS427le1L/DYSe3R (150 bp), 
5′-CTCATGATGAAAGAGAAGATGTTCAA-3′ and 5′-CTGTCAGGCC 
TTCGAGGA-3′; DYS 140e1L/DYS e45R (189 bp), 5′-TGCTGGCTGC 
TCTGAACTAA-3′ and 5′-GGCTTCCCAATTTTTCCTGT-3′; for EGFP, 
EGFPL/R (479 bp), 5′-CCTGAAGTTCATCTGCACCA-3′ and 5′-TGCTC 
AGGTAGTGGTTGTCG; for GAPDH (mouse and human), RPC1/2, 
5′-CCATCTTCCAGGAGCGAGA-3′ and 5′-TGTCATACCAGGAAA 
TGAGC-3′. For DNA transfection, FISH, generation of chimeric mice 
containing the DYS-HAC and immunofluorescence staining, see the 
Supplementary Materials and  Methods.
suPPleMentArY MAterIAls
Supplementary Materials and Methods.
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